Providing integrated drug discovery services to pharma, biotechnology companies and academic institutions. Read more
Assay Development and Screening
CE in Drug Discovery
Medicinal Chemistry
Selcia: Contract Research Services for the Life Sciences Industry
The leader in providing high quality radiolabelled (radiolabeled) compounds for your essential studies. Read more
14C Custom Synthesis
Radiolabelled (Radiolabeled) API for Clinical Trials
GLP Analytics
NEWS
03 April 2013
Selcia has developed new technology to enable drug discovery and development on the target family of peptidyl-prolyl cis-trans isomerases (PPIases).
15 February 2013
Read the article in Genetic Engineering and Biotechnology News GEN (15 Feb 2013, Vol. 44 No. 4) on Targeting Protein-Protein Interactions for an overview of some interesting contributions to the field including Selcia's Affinity Capillary Electrophoresis technology.
07 January 2013
Selcia Limited, leader dans la synthèse à façon de molécules radiomarquées et la fourniture de services de découverte de médicaments candidats, est heureuse d’annoncer qu’elle a reçu l’approbation du Crédit Impôt de Recherche Français pour les années 2012 a 2014.
EVENTS
Downloads
|
CEfrag™ Screen: Fragment Screening Using Capillary Electrophoresis – an Innovative and Useful Tool for the Fragment Screening Tool Box |
The Selcia Fragment Library (SFL) was designed to be universal and compatible with our proprietary CEfrag™ screen, a novel fragment screening technique based on capillary electrophoresis. |
14C Custom Radiosynthesis / Radiolabelled API for Clinical Trials / GLP Analytics / Metabolite Synthesis |
 A leading worldwide provider of integrated drug discovery, medicinal chemistry and 14-C custom radiolabelling services. |